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ARTICLE
Loss-of-Function and Gain-of-Function
Mutations in KCNQ5 Cause Intellectual
Disability or Epileptic Encephalopathy
Anna Lehman,1,* Samrat Thouta,2 Grazia M.S. Mancini,3 Sakkubai Naidu,4 Marjon van Slegtenhorst,3
Kirsty McWalter,5 Richard Person,5 Jill Mwenifumbo,1 Ramona Salvarinova,6 CAUSES Study,7 EPGEN
Study,7 Ilaria Guella,8 Marna B. McKenzie,8 Anita Datta,9 Mary B. Connolly,9
Somayeh Mojard Kalkhoran,2 Damon Poburko,2 Jan M. Friedman,1 Matthew J. Farrer,1,8
Michelle Demos,9 Sonal Desai,4 and Thomas Claydon2,*
KCNQ5 is a highly conserved gene encoding an important channel for neuronal function; it is widely expressed in the brain and gen-
erates M-type current. Exome sequencing identified de novo heterozygous missense mutations in four probands with intellectual
disability, abnormal neurological findings, and treatment-resistant epilepsy (in two of four). Comprehensive analysis of this potassium
channel for the four variants expressed in frog oocytes revealed shifts in the voltage dependence of activation, including altered activa-
tion and deactivation kinetics. Specifically, both loss-of-function and gain-of-function KCNQ5 mutations, associated with increased
excitability and decreased repolarization reserve, lead to pathophysiology.
Introduction
Potassium channels are ubiquitous in all eukaryotic cells
and serve multiple roles, including maintenance of cell
osmolality and volume, control of cell-membrane poten-
tials, and propagation of electrical signals in nerve cells.1
The largest and most diverse group of ion channels, potas-
sium channels, are tetrameric and span the lipid bilayer of
the cell membrane. Action potentials in nerve cells occur
via a process of polarization and repolarization, which is
modulated by many different subtypes of potassium chan-
nels. Each channel subtype has its own profile of kinetics,
voltage dependence, and sensitivity to pharmacologic
blocking agents. More than 90 human genes encode potas-
sium channel subunits with variable expression across tis-
sue types, and more than one-third of these genes are
known to cause human diseases when mutated. Review
of Online Mendelian Inheritance in Man reveals that
the range of clinical effects in various tissues is broad
and includes cardiac arrhythmia (e.g., KCNE1 [MIM:
176261], KCNE2 [MIM: 603796], KCNH2 [MIM: 152427],
and KCNJ2 [MIM: 600681]), sensorineural hearing
impairment (e.g., KCNE1, KCNQ1 [MIM: 607542], and
KCNQ4 [MIM: 603537]), retinopathy (e.g., KCNJ13
[MIM: 603208] and KCNV2 [MIM: 607604]), pulmonary
hypertension (KCNK4 [MIM: 605720]), insulin-secretion
defects (e.g., KCNJ11 [MIM: 600937]), hyperaldosteronism
(KCNJ5 [MIM: 600734]), Bartter syndrome (KCNJ1 [MIM:
600359]), dehydrated hereditary stomatocytosis (KCNN4
[MIM: 602754]), episodic ataxia (KCNA1 [MIM: 176260]),
spinocerebellar ataxia (KCNC3 [MIM: 176264] and
KCND3 [MIM: 605411]), epilepsy (e.g., KCNB1 [MIM:
600397], KCNC1 [MIM: 176258], KCNMA1 [MIM:
600150], KCNQ2 [MIM: 602235], KCNQ3 [MIM: 602232],
and KCNT1 [MIM: 608167]), and intellectual disability
(e.g., KCNA2 [MIM: 176262], KCNA4 [MIM: 176266],
KCNH1 [MIM: 603305], KCNJ6 [MIM: 600877], KCNJ10
[MIM: 602208], KCNK9 [MIM: 605874], and KCNQ2).
Voltage-gated potassium channels Kv7.1–Kv7.5 are en-
coded by KCNQ1–KCNQ5 (MIM: 607357), respectively.
Bi-allelic loss-of-function mutations in KCNQ1 cause Jer-
vell and Lange-Nielsen syndrome (sensorineural hearing
impairment with arrhythmia [MIM: 220400]), and hetero-
zygous mutations can cause a range of cardiac arrhythmias
or alter insulin secretion.2–4 KCNQ2 and KCNQ3 heterodi-
merize with one another; heterozygousmutations in either
gene can result in benign familial neonatal seizures (MIM:
121200 and 121201) or epileptic encephalopathy (MIM:
613720).5–7 There is evidence that Kv7.5 subunits can het-
erodimerize with Kv7.3 subunits.8 Mutations in KCNQ4
can cause autosomal-dominant sensorineural hearing
impairment.9
Material and Methods
Mutation of KCNQ5 was independently identified as a candidate
cause of intellectual disability or epileptic encephalopathy by
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four sequencing providers for four probands. GeneMatcher post-
ings, and subsequent communications, enabled independent
discoveries to be corroborated.10 Written informed consent for
exome sequencing and approval by ethics review boards were
obtained from Erasmus Medical Center (protocol MEC-2012387)
for individual 1 and from the University of British Columbia (pro-
tocols H-15-00092, H-09-01228, and H-14-01531) for individuals
2 and 4. Individual 3 received sequencing through clinical care,
and written informed consent was obtained for publication of
medical history.
For individual 1, genomic DNA was isolated from peripheral
blood of the proband, mother, and father, and exome-coding
DNA was captured with the Agilent Sure Select Clinical Research
Exome Kit. Reads were aligned to UCSC Genome Browser build
hg19 with the Burrows-Wheeler Aligner (BWA-MEM v.0.7.5a,
and variants were called with the Genome Analysis Toolkit
HaplotypeCaller (v.2.7-2). Detected variants were annotated,
filtered, and prioritized with the Bench Lab NGS v.3.1.2 platform
(Cartagenia). Individual 2 was exome sequenced through the
CAUSES (Clinical Assessment of the Utility of Sequencing and
Evaluation as a Service) study—a translational research study
seeking to apply exome sequencing as a hospital-based program-
matic service. Genomic DNA was isolated from peripheral blood
of the proband, mother, and father, and exome-coding DNA was
captured with the Agilent Sure Select All Exon V5þUTR Kit. The
products were sequenced on the Illumina HiSeq 2500 with v.4
chemistry. A customized bioinformatics pipeline,11 coupled
with visual validation (Integrative Genomics Viewer), identified
variants of interest. Individual 3 underwent trio-based Illumina
exome sequencing at GeneDx, a diagnostic laboratory certified
by the College of American Pathologists and Clinical Laboratory
Improvement Amendments. Genomic DNA was extracted from
whole blood from the affected child and parents. Exon targets
were isolated with the Clinical Research Exome (Agilent Technol-
ogies). Additional sequencing technology and a variant-interpre-
tation protocol have been previously described.12 The general
assertion criteria for variant classification are publicly available
on the GeneDx ClinVar submission page. Individual 4 was
enrolled in the Epilepsy Genetics Study (EPGEN)—a clinical
genetic study seeking to assess the utility and economy of
exome-based diagnostics in optimizing management of early-
onset epilepsy. Trio-based exome sequencing was performed on
DNA extracted from peripheral-blood lymphocytes with the Ion
AmpliSeq Exome Kit (57.7 Mb) and Ion Proton System, and then
genes linked or associated with seizure disorders underwent
bioinformatics analysis and prioritization.13 Variants were
confirmed with Sanger sequencing. Primer sequences are available
upon request. KCNQ5 variants were annotated on GenBank:
NM_001160133 (hg19).
Open-reading-frame full-length human cDNA sequences
(GenBank: NM_001160133) were custom synthesized
(GENEWIZ). Whole-cell membrane current recordings from Xeno-
pus oocytes expressing wild-type (WT) or mutant Kv7.5 constructs
were collected with a two-electrode voltage clamp and an OC-
725C amplifier (Warner Instruments). Signals were digitized and
acquired with a Digidata 1440 A/D converter and pClamp 10.2
software (Axon Instruments). Recordings were performed at
20C–22C, and oocytes were perfused with ND96 solution
(96 mM NaCl, 3 mM KCl, 0.5 mM CaCl2, 1 mM MgCl2, and
5mMHEPES titrated to pH 7.4 with NaOH) at 1 mL/min. For mea-
surement of activation properties, oocytes were held at 100 mV
and subjected to 3 s depolarizing steps to 50 mV in 10 mV incre-
ments. Instantaneous tail currents recorded during a subsequent
1 s step to 30 mV were used for generating conductance-voltage
(G-V) relationships. G-V relationships were described by the Boltz-
mann equation: y¼ 1/(1þ exp(V1/2V)/k), where y is the relative
conductance normalized to the maximum conductance
(G/Gmax), V1/2 is the voltage at which half maximal conductance
was recorded, V is the test voltage, and k is the slope factor. We
determined activation and deactivation kinetics by fitting the
rise in current upon depolarization (activation) and current decay
upon repolarization (deactivation) with an exponential function
at a range of voltages. Data were analyzed with Clampfit 10.3
(Axon Instruments) and SigmaPlot11 (Systat Software). Data are
presented as the mean5 SEM. The value n represents the number
of oocytes tested. Statistical significance was evaluated with a one-
way or two-way ANOVA followed by a Bonferroni post-test for
multiple comparisons.
Two approaches were taken for determining relative expression
levels of mutant channels. In the first, peak current amplitude
at þ40 mV was compared between mutant and WT channels at
the same time of day in the same batch of oocytes injected with
the same amount of cRNA. In the second approach, cell expression
of each construct was evaluated by immunocytochemistry.
HEK293 cells were plated on 12 mm glass coverslips and were
transfected with 1 mg of the channel cDNA in pCNDA3.1. All solu-
tions for immunohistochemistry were made in Dulbecco’s phos-
phate-buffered solution. Approximately 24 hr after transfection,
cells were fixed with 4% paraformaldehyde (room temperature,
15 min), permeabilized with 0.1% Triton X-100, blocked with
4% normal goat serum (1 hr), and stained overnight at 4C with
anti-Kv7.5 (1:500; C-terminal epitope, aa 880–897, Thermo Fisher
Scientific). The following day, cells were labeled with Alexa Fluor
647 Goat anti-Rabbit IgG (HþL) secondary antibody (1:500;
A-21245, Thermo Fisher Scientific), stained with Hoescht 33342
(1 mg/mL), and mounted in ProLong Gold. z stacks were acquired
at 0.2 mm steps on an inverted Nikon TiE epifluorescence micro-
scope with a Zyla 5.5 camera (Andor) and a CFI Plan Apo Lambda
1003 1.45 NA objective. Images were analyzed with Fiji. Kv7.5 im-
ages were background subtracted with a 600 nm rolling ball before
generation of a maximal intensity projection of the three slices
closest to the coverslip for best estimation of cell surface expres-
sion. Hand-drawn regions of interest were analyzed in two to
five fields of view per Kv7.5 variant. One-way ANOVA of mean
fluorescence intensity of labeling was performed in JMP (v.12.
SAS Institute).
Results
Two probands with non-syndromic intellectual disability
(individuals 2 and 3) and two with epileptic encephalopa-
thy (individuals 1 and 4) were identified as each having
a different heterozygous de novo missense variant
in KCNQ5 (GenBank: NM_001160133.1 and NP_
001153604): c.1343G>T (p.Ser448Ile) in individual 1,
c.434T>G (p.Val145Gly) in individual 2, c.1021C>A
(p.Leu341Ile) in individual 3, and c.1106C>G
(p.Pro369Arg) in individual 4. Each of these variants
was absent from gnomAD, and each was associated
with a high REVEL score (0.782 for c.1343G>T, 0.886
for c.434T>G, 0.827 for c.1021C>A, and 0.918 for
c.1106C>G).14 Additional in silico prediction programs
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(SIFT, MutationTaster, and PROVEAN) consistently indi-
cated that all four mutations would most likely be
damaging to the protein, except that PROVEAN predicted
c.1343G>T (p.Ser448Ile) to be neutral. An alignment with
Kv7.5’s paralogs, Kv7.2 and Kv7.3, also showed strong
expression in the brain, revealing that their encoding resi-
dues are uniformly maintained, except that an asparagine
replaces a serine at position 448 in KCNQ3 (Figure 1).
KCNQ5 demonstrates general intolerance of bothmissense
mutations and haploinsufficiency, as indicated by a Z score
of 4.62 for the former and a pLI score of 1.0 for the latter in
the Exome Aggregation Consortium (ExAC) Browser.15 All
variants were confirmed to be de novo in probands (absent
in parents) by Sanger capillary sequencing.
There were no suspicious variants of interest in individ-
uals 1, 3, or 4 in addition to de novo variants in KCNQ5. An
additional maternally inherited variant of uncertain signif-
icance (c.214C>G [p.Glu72Gln]) was identified in SYP on
chromosome X in individual 2 (male). The phenotype
associated with SYP loss of function appears to be non-syn-
dromic intellectual disability.16 This variant is not reported
in public databases, but two hemizygotes for a different
change at the same residue, p.Glu72Lys, are recorded in
gnomAD.15 Furthermore, the composite REVEL score is
low (0.232), suggesting that the variant is likely to be
non-damaging.
Comparison of phenotypes showed similarities among
the four individuals, including absence of dysmorphic fea-
tures, hypotonia, intellectual disability, and impaired coor-
dination or unsteady gait (Table 1). Individuals 2 and 4
both had treatment-resistant epilepsy, and individual 4
had the additional feature of cortical atrophy, along with
a greater degree of neurological impairment and being
non-ambulatory and dependent on a jejunostomy tube
for nutrition. At 5 months of age, individual 4 developed
infantile spasms with hypsarrhythmia on electroencepha-
lography (EEG) and an electrodecremental pattern during
epileptic spasms. Spasms were unresponsive to vigabatrin,
adrenocorticotropic hormone (ACTH), prednisone, and
pyridoxine. She subsequently developed myoclonic-tonic,
myoclonic, and tonic seizures. The following therapies
were ineffective: topiramate, lamotrigine, phenobarbital,
valproic acid, nitrazepam, clobazam, clonazepam, levetira-
cetam, piracetam, ethosuximide, sulthiame, carbamaze-
pine, oxcarbazepine, acetazolamide, lacosamide, rufina-
mide, gabapentin, and the ketogenic diet. The longest
seizure-free period was 2 weeks on ACTH. Hypsarrhythmia
persisted for several months, and EEG evolved to a pattern
with no posterior dominant rhythm, generalized delta
activity, generalized sharp-and-slow-wave complexes, or
multifocal sharp waves and spikes. Seizures characterized
by a myoclonic jerk followed by generalized body and
limb stiffening and eye deviation to the left were recorded
in association with a generalized sharp wave followed by
an electrodecremental pattern. Myoclonic seizures were re-
corded with generalized sharp waves. At the most recent
follow-up at age 11 years, she was having multiple seizures
daily and was on six anti-seizure medications.
Seizure types for individual 1 included absence and
focal-onset seizures with impaired awareness. From the
age of 2 years, he developed seizures initially characterized
by short periods of staring, sometimes followed by exten-
sion of both arms, shouting, and focal limb jerks, without
post-ictal phenomena; later in childhood, the attacks pro-
gressed to loss of consciousness and generalized tonic
seizures. EEG confirmed diffuse epileptic activity. Despite
treatment with valproate and lamotrigine, he continues
to experience almost daily attacks of decreased awareness,
Figure 1. Partial Clustal Omega Alignments of Kv7.5, Kv7.2, and Kv7.3
Residues with missense variants in the subject cohort are labeled and boxed. UniProt identifiers are labeled to the left of the protein
name; note that the numbering of UniProt: Q9NR82 for Kv7.5 is different for Ser448 than the numbering of the canonical GenBank:
NP_001153604, referred to elsewhere in this manuscript. These residues are strongly constrained, although Kv7.3 features an alternate
amino acid for Ser448. In its entirety, Kv7.5 shares 50% identity with Kv7.2 and Kv7.3.
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Table 1. Phenotypic Findings from Clinical Histories, Physical Examination, Brain Imaging, and EEG
Individual 1 Individual 2 (CAUSES 053) Individual 3 Individual 4 (EPGEN 013)
KCNQ5 variant (GenBank) c.1343G>T (p.Ser448Ile)
(NM_001160133)
c.434T>G (p.Val145Gly)
(NM_001160133)
c.1021C>A (p.Leu341Ile)
(NM_001160133)
c.1106C>G (p.Pro369Arg)
(NM_001160133)
Age at last follow up 14 years 11 years 5 years 10 years
Family history negative for neurodevelopmental
disorders
negative for neurodevelopmental
disorders
relatively uninformative, paternal
cousin with developmental delay,
ID, and microcephaly
negative for neurodevelopmental
disorders
Ancestry Southeast Asian Southeast Asian South Asian and European Southeast Asian
Gender male male male female
Delivery uncomplicated term SVD uncomplicated term SVD term C-section for signs of fetal
distress
uncomplicated term C-section
Birth weight 3,430 g 3,402 g unknown 3,060 g
Ambulation unstable ataxic gait achieved at 18 months, normal gait,
unable to tandem walk
achieved at 18 months, walks
on toes, unstable
nonambulatory
Language no speech simple sentences limited speech nonverbal
ID severity severe mild mild to moderate severe to profound
Seizures from the age of 2 years, absence and
focal-onset seizures with impaired
awareness and uncontrolled by
multiple AED
none none onset at 5 months, epileptic
encephalopathy, infantile spasms
followed by tonic seizures,
treatment resistant
EEG high voltage, diffusely slow
background pattern, sharp waves
and peak waves in frontal areas
normal EEG at age 11 years normal abnormal dysrhythmic background
and multifocal epileptiform activity
at age 9 years
Other neurological abnormalities decreased deep tendon reflexes, mild
hypotonia, pronounced sleepiness
non-REM parasomnias, hypotonia,
incontinence
mild axial hypotonia reduced visual attentiveness, axial
hypotonia, spasticity in limbs
Brain MRI normal at 7 years normal at 9 years normal at 3 years progressive atrophy
Height 142 cm (2 SD) 138.5 cm (1.05 SD) 100 cm (1.75 SD) 131 cm (1.75 SD)
Weight 29 kg 25.1 kg 15.6 kg 26 kg
Head circumference 53 cm (1 SD) 50 cm (2 SD) 50.5 cm (1 SD) 48.5 cm
Morphology normal normal normal normal
Other none two small simple cysts in left kidney atopic dermatitis explained by
an FLG variant on exome
fed via jejunostomy tube
Abbreviations are as follows: AED, anti-epileptic drug; EEG, electroencephalography; ID, intellectual disability; REM, rapid eye movement; and SVD, spontaneous vaginal delivery.
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Figure 2. Heterologous Expression of Homomeric WT and Mutant Kv7.5 Channels
(A) Representative current traces forWT, p.Val145Gly (V145G), p.Leu341Ile (L341I), p.Ser448Ile (S448I), and p.Pro369Arg (P369R) Kv7.5
were recorded in Xenopus laevis oocytes during 3 s depolarizations from 100 to 40 mV in 10 mV increments, followed by a 1 s step
to 30 mV. The holding potential was 100 mV.
(B) Conductance-voltage relationships forWTandmutant channels determined from instantaneous tail current amplitudes. Lines repre-
sent fits of the data with a Boltzmann function. V1/2 and k values were 46.25 1.8 mV and 10.85 0.8 mV (n ¼ 7) for the WT. Corre-
sponding values were 38.8 5 1.1 and 18.4 5 0.2 mV (n ¼ 7) for p.Val145Gly, 42.9 5 1.2 and 7.0 5 0.2 mV (n ¼ 5) for
p.Leu341Ile, 46.65 1.1 and 12.3 5 1.2 mV (n ¼ 6) for p.Ser448Ile, and 775 0.8 and 7.65 0.3 mV (n ¼ 5) for p.Pro369Arg.
(C and D) Activation kinetics for WTandmutant channels. Activating currents over a range of voltages were fitted to a double exponen-
tial function to yield values for tfast (C) and tslow (D) of activation. tslow values were largely voltage independent and unaffected by the
variants, except for p.Pro369Arg.
(legend continued on next page)
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shaking, facial cramps, and unnatural laughter. Sleep
disturbance affects individuals 1 and 2.
We searched previously published datasets of large-
scale sequencing studies on the causes of neurodevelop-
mental disability for other reports of de novo KCNQ5 mu-
tations and found c.867G>T (p.Lys289Asn), c.1328G>A
(p.Arg443Gln), and c.1727A>G (p.His576Arg) in the sup-
plemental data from 820 probands in Lelieveld et al.17
However, these variants were not identified as candidate
causes of neurodevelopmental disability in the course of
the authors’ statistical analyses. The largest currently pub-
lished cohort of individuals with developmental disorders
(the Deciphering Developmental Disorders study, n ¼
4,293) did not feature any KCNQ5 de novo variants,18
nor were any included in the data from the cohort of
2,508 autism probands from Iossifov et al.19
Because of the above evidence associating KCNQ5muta-
tions with neurodevelopmental disorders, as well as prior
evidence that mutations in KCNQ2 (encoding Kv7.2) and
KCNQ3 (encoding Kv7.3) most likely cause neurological
disease via reduced basal M-current (and subsequent
neuronal hyperexcitability),20 the impact of each muta-
tion was characterized in vitro. Figure 2 shows that
heterologous expression of homomeric WT Kv7.5 chan-
nels yielded voltage-dependent Kþ currents that activated
slowly upon depolarization with a V1/2 of activation
of 46.2 5 1.8 mV (n ¼ 7), as has been described
previously.8,21 All four aberrant proteins exhibited robust
functional expression when expressed as homomers.
Compared with WT channels, each altered channel modi-
fied gating properties (Figures 2 and 3), and this was
evident in the activation (Figure 2A) and deactivation
(Figure 3A) current traces. The p.Val145Gly variant,
located in the voltage-sensing unit of the channel (S1),
led to subtle effects on channel function. The voltage
dependence of activation was not significantly altered
from that of the WT (V1/2 ¼ 38.8 5 1.1 mV, n ¼ 7; not
significant [NS], ANOVA; Figure 2B). However, compared
with WT channels, p.Val145Gly slowed early activation
at depolarized voltages (Figure 2C) and deactivation
kinetics (Figure 2B) across the entire voltage range tested
(p < 0.05, two-way ANOVA; Figure 3B). In addition,
p.Val145Gly reduced channel expression. Relative func-
tional expression (Figure 2E) was reduced by 50% 5 7%
(n¼ 7; p< 0.01), and immunocytochemistry labeling (Fig-
ures 2F and 2G) suggested that protein levels were reduced
by 45% 5 7% (p < 0.05). Compared with the WT,
p.Leu341Ile (S6, pore domain) did not alter the V1/2 of acti-
vation (V1/2 ¼ 42.1 5 1.2 mV, n ¼ 5; NS, ANOVA;
Figure 2B); however, activation in the subthreshold range
of the action potential (60 and 50 mV) was shifted
to more depolarized potentials. Furthermore, compared
with WT channels, p.Leu341Ile channels slowed the early
phase of activation (Figure 2C) and deactivation kinetics
(Figure 3B) at all voltages (p < 0.05, two-way ANOVA).
Moreover, in a manner similar to p.Val145Gly, p.Leu341Ile
reduced functional channel expression (Figure 2E) by
45%5 5% (n ¼ 9; p < 0.05) and protein immunolabeling
(Figures 2F and 2G) by 40% 5 2%. Like p.Val145Gly,
p.Ser448Ile (C terminal) channel function was subtly
altered. Activation kinetics were significantly slower than
those of WT channels at depolarized potentials (p < 0.05,
two-way ANOVA; Figure 2C), although no differences
were observed in the voltage dependence of activation or
the kinetics of deactivation (Figures 2B and 3B). Channel
expression was also not affected. The functional expres-
sion level relative to the WT level was 130% 5 22%
(n ¼ 6, NS; Figure 2E), and immunolabeling showed
protein levels to be not significantly different from
those of WT Kv7.5 (Figures 2F and 2G). In contrast,
p.Pro369Arg (C terminus) shifted the voltage dependence
of activation by 30 mV in the hyperpolarizing direction
(V1/2 ¼ 77.0 5 0.8 mV, n ¼ 5; p < 0.05, ANOVA;
Figure 2B). Corresponding to this pronounced shift, the
kinetics of both early and late phases of activation were
significantly accelerated (p < 0.05, two-way ANOVA; Fig-
ures 2C and 2D). Deactivation kinetics were slowed by
the variant (Figure 3B). Channel expression was not
affected by the variant. The functional expression level
relative to the WT level was 74% 5 12% (n ¼ 6, NS;
Figure 2E), and immunolabeling of protein levels was not
different from that of WT Kv7.5 (Figures 2F and 2G).
Discussion
Mutations in KCNQ5 (encoding Kv7.5) can result in
a congenital neurological disorder with intellectual
disability or epileptic encephalopathy. Mutations in other
KCNQ homologs, KCNQ2 and less commonly KCNQ3, can
also result in epilepsy either by loss-of-function or by gain-
of-function effects.7,22–24 In neurons, Kv7.5 is important
for regulation of theM-type current, and hence firing rates.
The M-current is a slowly activating and deactivating
neuronal potassium current that plays a crucial role in
regulating neuronal excitability by impeding repetitive
(E) Relative functional channel expression. Mean current amplitudes of homomeric WT and mutant Kv7.5 channels were compared at
the end of a 3 s voltage step to þ40 mV. Current amplitudes from mutant channels were normalized to the current amplitude of WT
Kv7.5 channels recorded from oocytes injected with the same amount of cRNA on the same day. A t test with day as a blocking factor
and mutant as a treatment factor was used to compare mutant and WT expression. All data represent the mean5 SEM, and *p < 0.05.
(F) Representative epifluorescence images from HEK293 cells transfected with WT Kv7.5 or the identified channel mutant. Hoescht
33342 labeling of nuclei is in blue, and Kv7.5 channel staining is in white.
(G) Mean relative fluorescence intensity measured from two to five images as in (F). Fluorescence values relative to those of WT Kv7.5
were 0.55 5 0.07 for p.Val145Gly, 0.60 5 0.02 for p.Leu341Ile, 0.965 0.04 for p.Pro369Arg, and 0.895 0.04 for p.Ser448Ile.
All data shown are presented as the mean5 SEM.
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action-potential firing during long-lasting depolarizing in-
puts. Inhibition of M-currents leads to enhanced neuronal
excitability associated with a wide spectrum of early-onset
epileptic disorders ranging from benign familial neonatal
convulsions to severe epileptic encephalopathies and/or
intellectual disability.25 A dominant-negative Kcnq5muta-
tion in mice has been shown to alter synaptic inhibition
and excitability in the hippocampus, an area of high
expression, although seizures were not observed.26,27
Given this background, we hypothesized that M-current
couldbeadversely affectedbyKCNQ5mutations andsought
electrophysiologic confirmation. Xenopus laevis oocytes are
a useful model system given that heterologous expression
of KCNQ2 and KCNQ3 has been shown to recapitulate the
biophysical and pharmacological profile of native M-cur-
rents.28 Electrophysiological characterization of mutant
andWTchannels in the heterologous expression system of
Xenopus oocytes showed that these four KCNQ5mutations
Figure 3. Deactivation Gating of Homo-
meric WT and Mutant Kv7.5 Channels
(A) Representative deactivating tail cur-
rent traces for WT, p.Val145Gly (V145G),
p.Leu341Ile (L341I), p.Ser448Ile (S448I),
and p.Pro369Arg (P369R) Kv7.5 were re-
corded in Xenopus laevis oocytes during a
range of test voltages applied after a 3 s
depolarization step to 0 mV to activate
channels. The inset shows the super-
position of normalized tail current traces
from WT and mutant Kv7.5 channels
recorded at 140 mV to highlight the
change in deactivation.
(B) Deactivation kinetics for WT and
mutant channels. Tail current decays
were fitted to a double exponential func-
tion to yield the values for tfast and tslow
of deactivation. Mean tweighted (derived
from the sum of tfast and tslow weighted
according the relative amplitude of each
component) of the deactivating currents
were plotted over a range of voltages.
All data represent the mean 5 SEM, and
*p < 0.05.
All data shown are presented as the
mean5 SEM.
all alter channel gating properties,
producing a loss-of-function pheno-
type in three cases and a gain of func-
tion in another case (c.1106C>G
[p.Pro369Arg]). The obtained results
suggest that the primary consequence
of KCNQ5 mutations is a change in
the gating properties of M-channels.
The most pronounced pheno-
typic disturbance was observed in
p.Pro369Arg channels, present in
the most severely affected child, indi-
vidual 4. Compared with the WT,
p.Pro369Arg stabilized the activated
state of the channel (left shifted the activation curve;
Figure 2B), accelerated activation kinetics (Figure 2C
and D), and slowed deactivation kinetics (Figure 3B), in
keeping with a straightforward gain of function in the
mutant channels. This effect is strikingly similar to the ac-
tion of the Kv7-channel-activator compound, retigabine,
which induces a pronounced left shift of the activation-
voltage relationship in M-currents recorded from sympa-
thetic neurons.29 Increased function of M-currents has
been suggested to increase neuronal excitability,7 which
could be due to overactivation of hyperpolarization-
activated non-selective cation channels, resulting in
secondary depolarizations.30 The dramatic stabilization of
activated states in comparison with closed states, induced
by Kv7.5 p.Pro369Arg, is predicted to increase excitability
and helps explain the severe phenotype of individual 4. It
is also of interest to note the strikingly different seizure phe-
notypes between individuals 4 and 1, the former of whom
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has infantile spasms and tonic seizures and the latter of
whom has focal-onset seizures with impaired awareness.
Thep.Val145Gly andp.Leu341Ile alterations resulted in a
depolarizing shift of the activation curve (Figure 2B) accom-
panied by a dramatic slowing of early activation kinetics
(Figure 2C). Furthermore, channel expression was signifi-
cantly reduced in both cases. These effects are characteristic
of a loss-of-function effect.22–24 The severity of the loss-of-
function phenotype in these mutant channels is possibly
lessened by the slowed deactivation kinetics caused by the
mutations, which would be predicted to increase repolariz-
ing currents and reduce action-potential firing; however,
the reduced channel expression would be expected to
dominate. Channels with p.Ser448Ile also slowed the ki-
netics of early activation and are therefore likely to produce
a loss of function. This variant did not alter channel expres-
sion and had themildest effect of the four variants studied.
Consistent with previous findings on KCNQ2mutations,22
reduced function of Kv7.5 channels resulting from these
variants is predicted to cause a lowered seizure threshold
as a result of decreased neuronal repolarization reserve
mediated by the M-current.
From a structure-function perspective, it is interesting
that variants in the S6 pore and C terminus, as well as
within the voltage-sensing unit (S1), modify the voltage
dependence of activation gating and/or its kinetics. The ef-
fect of p.Pro369Arg, in particular, suggests that the prox-
imal C-terminal region can dramatically influence the
stability of the open state of these channels. It is also
interesting that activation and deactivation gating are
apparently independently altered by p.Val145Gly and
p.Leu341Ile; in these cases, both activation and deactiva-
tion were slowed, suggesting that these processes are inde-
pendently influenced by the variants.
The effects of co-assembly of altered subunits and WT
Kv7.5 subunits have yet to be explored. Kv7.5 subunits
might also co-assemble with Kv7.3 subunits in vivo to
contribute to the M-current,8,21 as well as KCNE1 and
KCNE3 (MIM: 604433), which are endogenously expressed
in Xenopus oocytes, and we have not explored the effect of
the de novo mutations in such protein complexes.
Our data demonstrate that KCNQ5 mutations that
interfere with channel function most likely cause a
congenital neurodevelopmental disorder with pheno-
types of nonsyndromic intellectual disability or epileptic
encephalopathy. The experimental and in silico evi-
dence is particularly strong for c.434T>G (p.Val145Gly),
c.1021C>A (p.Leu341Ile), and c.1106C>G (p.Pro369Arg)
and less so for c.1343G>T (p.Ser448Ile). Future research
should explore genetically and structurally informed
pharmacological interventions.
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